Cite

HARVARD Citation

    Sabatier, R. et al. (2023). Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. European journal of cancer. pp. 42-52. [Online]. 
  
Back to record